National Working Committee for Bioequivalence (BE) Study

Star InactiveStar InactiveStar InactiveStar InactiveStar Inactive
 

Implementation of Bioequivalence Study Requirement in Malaysia

In line with the Ministry of Health objectives of ensuring quality, efficacy and safety of pharmaceutical products that are marketed, the Drug Control Authority at its 92nd Meeting has decided to review the registration of generic products to include Bioequivalence (BE) studies requirements for certain categories oral immediate release products. 

 

History

The National Working Committee for bioequivalence (BE) study was formed in September 1999. The committee comprised of representatives from University Malaya (UM), Universiti Sains Malaysia (USM), Universiti Kebangsaan Malaysia (UKM), International Medical University (IMU), National Pharmaceutical Regulatory Agency (NPRA) and the pharmaceutical industry. The members were officially appointed to undertake the task of formulating an action plan for the conduct of BE studies in Malaysia through collaborative efforts.

Publication of the 'Malaysian Guidelines for the Conduct of Bioavailability and Bioequivalence Studies' marked the first outcome of this committee's objectives. This guideline is to provide guidance to the local researchers in conducting BE Studies in accordance to established international standards. Implementation of this guideline will promote properly designed studies being carried out. 

 

Objective and Scope  

The National Working Committee for Bioequivalence Study was formed with the objective to

  1. Discuss, BE related issues and to endorse recommendations to these issues based on suggestion by the TWG BE through cooperative effort.
  2. Establish positions and advocate recommended courses of action to the Drug Control Authority (DCA) on potential emerging issues, and prepare relevant documents regarding the issues of regulatory

The Working Committee's scope includes

  1. Reviewing national and international requirements related to the conduct of bioequivalence study;
  2. Identifying active ingredients/ products which require BE studies. This may include to identify and recommend suitable BE comparator products for BE studies in Malaysia.
  3. Ensuring the conduct or implementation of the BE studies are in accordance to the guidelines and timelines.
  4. Assisting to publish the DCA approved materials pertaining to BE, when necessary.

National Pharmaceutical Regulatory Agency (NPRA)
Lot 36, Jalan Universiti, 46200 Petaling Jaya, Selangor, Malaysia.
  • Email: npra@npra.gov.my
  • Phone: +603-7883 5400
  • Fax: +603-7956 2924, +603-7956 7075

DISCLAIMER

The Government of Malaysia and the National Pharmaceutical Regulatory Agency are not responsible for any loss or damage caused by the usage of any information obtained from this website.

Mobile Web :

Site Last Modified

  • Last Modified: Monday 30 November 2020, 15:04:44.
© Copyright 2019 . All Rights Reserved National Pharmaceutical Regulatory Agency NPRA

Main Menu English

Choose Your Language